{
    "articleURL": "/wires/reuters/article-12042819/BRIEF-GSK-Estimates-Over-10-Mln-People-In-U-S-Will-Receive-Cos-Or-Pfizer-S-RSV-Vaccine-This-Year.html",
    "content": [
        "May 3 (Reuters) - GSK plc:",
        "* GSK ESTIMATES MORE THAN 10 MILLION PEOPLE IN U.S. WILL RECEIVE ITS OR PFIZER\u00b4S RSV VACCINE THIS YEAR - CCO* GSK CCO SAYS CDC ADVISORY PANEL LIKELY TO APPROVE ITS RSV VACCINE FOR ADULTS OVER 60 WITH COMORBIDITIES IN ADDITION TO ADULTS OVER 65* GSK CCO SAYS HOPES RSV VACCINE WILL BE PRICED ABOVE $120 PER SHOT IF DATA EXPECTED SOON SHOWS VACCINE PROTECTS FOR TWO RSV SEASONS* GSK EXECUTIVE SAYS DOES NOT EXPECT MUCH UPTAKE OF RSV VACCINE IN EUROPE THIS YEAR AS NATIONAL PAYER NEGOTIATIONS WON'T HAPPEN IMMINENTLY* GSK EXEC EXPECTS RSV VACCINE TO BE AVAILABLE BEFORE NEXT RSV SEASON IN UNITED STATES IF APPROVED BY THE FDA Further company coverage:"
    ]
}